Why Contraceptive Innovation?

Despite the availability of various contraceptive methods, more than 200 million women in developing countries want to avoid or delay pregnancy yet are not using an effective family planning method. For some of these women, access to contraception is limited. For others, currently available methods do not meet their needs or preferences or are unaffordable. Innovative solutions are needed in the areas of product development, registration, pricing, and introduction to address these barriers.

Join the exchange and become part of the solution!

Visit our resource library for additional information about the need for contraceptive innovation.


A one-stop shop for resources related to contraceptive research and development

The CTI Exchange offers resources about contraceptive research and development, including information about products currently in development, preclinical and clinical research, and opportunities for future investment. This easily searchable resource library also includes information about regulatory requirements, quality assurance standards, intellectual property, and product introduction strategies, as well as tools for advocacy.

View all resources


Latest news, events, resources, and thought pieces from the Exchange's blog


New summer Twitter campaign: #NextGenContraception
The CTI Exchange’s summer social media campaign aims to highlight the importance of new contraceptive research and development to meet the needs and preferences of women and men globally. ...

Upcoming Webinar Series: “Mind the Gap”
The Reproductive Health Supplies Coalition is hosting a webinar series, titled “Mind the Gap”, on their latest Global Contraceptive Commodity Gap Analysis (CGA 2018).

NIH Announces Funding for Novel Contraceptive Methods
The National Institutes of Health has released a new funding solicitation to support the development of novel nonsteroidal contraceptive methods.

Contraceptive Technology Innovation: A Wise Investment
As long as women and men find current family planning methods unacceptable, unaffordable, or inaccessible, there will be a need to invest in contraceptive technology innovation.

Contraceptive Technology Innovation: It’s Everyone’s Business
Everyone must be engaged to move the science of contraceptive technology innovation forward – to bring it out of the laboratories and get it to the people who need it on the ground.

Upcoming Webinar: “Imagining the future of women’s contrace...
This month, the Reproductive Health Supplies Coalition will twice host the webinar: “Imagining the future of women’s contraception: Results from the CT Innovation Lab Workshops in Kenya ...

Ferring Pharmaceuticals to Issue Biomarker Research Grants
Applications for Ferring Pharmaceuticals’ Innovation Grants Program to support biomarker research are due June 11. 

Getting Behind Human-Centered Design for Contraceptive Innovation
With high unmet need for family planning methods still present, a huge opportunity exists to look at new ways to design products that respond to women’s needs and preferences, rather than ...

Vaginal Rings: The Future is Now
Successes and lessons learned from Progering and Dapivrine —the first vaginal rings to be introduced—will be critical in informing the introduction of the rings currently in development.

Blocking Sperm by Reinforcing Cervical Mucus
How novel would it be if one of women’s own natural barriers – cervical mucus – could be the basis for a highly effective, game-changing contraceptive.

Sperm Motility Inhibited in Study of Male Macaques
Newly published research suggests that EP055 could become the basis for an effective, reversible, short-acting, non-hormonal male contraceptive.

Building the Foundation for Developing Next-Gen Contraceptives
Discovery of new contraceptive agents will remain elusive unless something changes to dramatically improve the state-of-the-art for contraceptive screening and pre-clinical testing, making t...

Featured Resources

Other key resources related to contraceptive research and development

Calliope, the Contraceptive Pipeline Database, includes information on potential contraceptive targets and leads, products in development, and a selection of products only available in limited markets.
CAPRI, the Contraceptive Active Pharmaceutical Ingredient Database, lists biological and chemical properties for 27 active pharmaceutical ingredients found in contraceptives, along with data on their pharmacology, toxicology, impurities, metabolites, and use in marketed products.
Contraceptive Drug Interactions is a database that catalogues potential interactions between contraceptive drugs and drugs from other therapeutic classes. Changes in drug pharmacokinetics, effectiveness, and adverse effects are provided.


We want you to join the exchange!

The CTI Exchange looks to partners to help generate and share resources. Contact us with your ideas, materials, or questions, or sign up to receive more information. We also encourage you to provide your feedback